New drug combo shows promise for tough lung cancer
NCT ID NCT02523469
First seen Feb 18, 2026 · Last updated May 25, 2026 · Updated 15 times
Summary
This study tested a combination of two drugs, nivolumab and ALT-803, in 67 patients with advanced non-small cell lung cancer that had already been treated. The goal was to find a safe dose and see how many patients' tumors shrank. The approach aims to boost the immune system to fight the cancer, but ongoing treatment is typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Cleveland Clinic Florida
Weston, Florida, 33331, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.